GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CEL-SCI Corp (AMEX:CVM) » Definitions » 10-Year RORE %

CVM (CEL-SCI) 10-Year RORE % : -45.47% (As of Jun. 2024)


View and export this data going back to 1991. Start your Free Trial

What is CEL-SCI 10-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. CEL-SCI's 10-Year RORE % for the quarter that ended in Jun. 2024 was -45.47%.

The industry rank for CEL-SCI's 10-Year RORE % or its related term are showing as below:

CVM's 10-Year RORE % is ranked worse than
89.15% of 590 companies
in the Biotechnology industry
Industry Median: -6.205 vs CVM: -45.47

CEL-SCI 10-Year RORE % Historical Data

The historical data trend for CEL-SCI's 10-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CEL-SCI 10-Year RORE % Chart

CEL-SCI Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
10-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -10.83 -35.17 -30.80 -29.55 -39.05

CEL-SCI Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
10-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -38.41 -39.05 -42.63 -45.51 -45.47

Competitive Comparison of CEL-SCI's 10-Year RORE %

For the Biotechnology subindustry, CEL-SCI's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CEL-SCI's 10-Year RORE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CEL-SCI's 10-Year RORE % distribution charts can be found below:

* The bar in red indicates where CEL-SCI's 10-Year RORE % falls into.



CEL-SCI 10-Year RORE % Calculation

CEL-SCI's 10-Year RORE % for the quarter that ended in Jun. 2024 is calculated as:

10-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 10-year -Cumulative Dividends per Share for 10-year )
=( -0.58--11.96 )/( -25.03-0 )
=11.38/-25.03
=-45.47 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jun. 2024 and 10-year before.


CEL-SCI  (AMEX:CVM) 10-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


CEL-SCI 10-Year RORE % Related Terms

Thank you for viewing the detailed overview of CEL-SCI's 10-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


CEL-SCI Business Description

Traded in Other Exchanges
Address
8229 Boone Boulevard, Suite 802, Vienna, VA, USA, 22182
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company's core capabilities that include are drug discovery, research, development and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.
Executives
Geert R Kersten director, officer: Chief Executive Officer 8229 BOONE BLVD, STE 802, VIENNA VA 22182
Patricia B Prichep officer: Sr. Vice President, Operations 8229 BOONE BLVD., SUITE 802, VIENNA VA 22182
Robert Eugene Watson director 245 N. HIGHLAND AVE NE, SUITE 230-296, ATLANTA GA 30307
Gail K Naughton director C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
Peter R Young director 8229 BOONE BLVD, STE 802, VIENNA VA 22182
John Cipriano officer: Senior Vice President 8229 BOONE BLVD, SUITE 802, VIENNA VA 22182
Bruno Jean-marie Baillavoine director 8229 BOONE BLVD., SUITE 802, VIENNA VA 22182
Eyal Talor officer: Chief Scientific Officer 8229 BOONE BLVD, STE 802, VIENNA VA 22182
Daniel H Zimmerman officer: Sr. Vice President, Research 8229 BOONE BLVD, STE 802, VIENNA VA 22182
Clara Maximilian De director, officer: President
C Richard Kinsolving director 8229 BOONE BLVD, STE 802, VIENNA VA 22182
Alexander G Esterhazy director 8229 BOONE BLVD, STE 802, VIENNA VA 22182